Endpoints News' John Carroll and DealForma’s Chris Dokomajilar are back with our latest ranking of the top 100 VCs looking to make their mark in the biotech world. And we’re highlighting the occasion with a special webinar that will focus in on the field, which has been struggling with an IPO drought and the deep chill that has turned investors to other fields. Is this the big turnaround year? How do you raise new rounds and form new syndicates in this market? What are the institutional investors saying about biotech when ultra-safe investments are available? We’re getting some of the top investment experts in biotech to join this roundtable discussion. You can sign up here.
Chris leads strategy, operations, data analytics, and content development. Prior to founding DealForma, Chris held research, management consulting, and industry analytics roles within biopharma at UCSF, Recap, Deloitte, Thomson Reuters, and BioCentury. He enjoys the opportunity to contribute to industry thought-leadership and is frequently invited to speak to industry groups about biopharma business development and licensing. Chris holds degrees from the University of California Berkeley.
Andrew Lam, Pharm.D., is a Principal at Ally Bridge Group (ABG) and focuses on biotech investing. Before joining Ally Bridge Group, Andrew was Senior Director of Business Development at Intercept Pharmaceuticals, Vice President in the Healthcare Investment Banking Group at Jefferies, and Equity Research Associate at BMO Capital and Canaccord Genuity. Andrew spent the first part of his career at several biopharmaceutical companies, including Celgene and Shire, in Medical Affairs.
He has led many of ABG’s Biotech investments, including Arbor Biotechnologies, CARGO Therapeutics (CRGX), CG Oncology (CGON), Endeavor BioMedicines, ProfoundBio, RayzeBio (acquired by BMS), Shoreline Biosciences and Sonoma Biotherapeutics. He is currently serving as a director on the board of directors for Endeavor BioMedicines and ProfoundBio. Andrew holds a Pharm.D. from Long Island University and an MBA from Drexel University. Andrew currently serves on the scientific advisory board of Curebound.
Tess Cameron is a Principal on the Investment Team at RA Capital Management. Tess works on both public and private investments and serves on several company boards. Previously, Tess held finance leadership roles at Foghorn Therapeutics, Wave Life Sciences, and Biogen. Prior to joining biotech/pharma, she was a specialist in the corporate finance team at McKinsey & Co, focused on corporate transactions. Tess has a BA with a double major in Economics and Peace & Conflict studies from the University of Toronto, Canada.
Nessan is an Operating Partner at Khosla Ventures focused on life science companies with an emphasis on nucleic acid editing, novel delivery systems, gene and cell therapy, novel target identification and data analytics for drug discovery and development.
Having founded multiple companies in the life sciences realm, Nessan is a serial biotech entrepreneur and investor. Most notable among his companies are Intellia Therapeutics, a top-10 biotech startup in 2014, Triplet Therapeutics, and Korro Bio. At Intellia, Nessan served as president and CEO from inception through 2017, leading the company from concept through partner deals, multiple financing rounds and an IPO prior to its second anniversary.
Nessan also held investment roles at Atlas Venture and Omega Fund Management, where he successfully invested in and managed multiple investments across the United States and Europe. He is currently the chairman of F-star and executive chair at Everyone Medicines, Korro Bio and Stylus Biomedicine. He also currently sits on the board of CellFE, Deep Genomics, Liberate Bio and Ochre Bio and is a board observer with CHARM Therapeutics.
Previously he was a member of the equity research team at UBS, an independent advisory board member of the California Institute of Regenerative Medicine (CIRM) and MerckSerono KGaA. He received his Ph.D. in Molecular Biology from Imperial College London, and was a Howard Hughes Associate Fellow at Baylor College of Medicine.
John D. Carroll is a biotech analyst and writer with decades of prize-winning experience in journalism. A co-founder of Endpoints News, he has covered biopharma for the past 15 years. Aside from his daily industry coverage for FierceBiotech, where he was named editor in 2003, leaving in 2016, Carroll has been a regular speaker at biotech events around the globe. He’s been quoted by The New York Times, The New Yorker, Financial Times, The Times of London and more. He’s also keynoted at biotech gatherings around the world and addressed student audiences at MIT and Harvard. Carroll has contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press. He spent 6 years as editor and publisher of the Dallas Business Journal, was publisher of Texas Business and early in his career was part of a Pulitzer Prize-winning team of reporters and editors at the Kansas City Star & Times.